A Randomised, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of MT-4129 in Healthy Subjects; Including the Effect of Gender and Age on the Pharmacokinetics of a Single Dose of MT-4129 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 23 May 2017
At a glance
- Drugs MT 4129 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 16 May 2017 Status changed from recruiting to completed.
- 11 Dec 2016 Status changed from not yet recruiting to recruiting.
- 10 Nov 2016 New trial record